周圣斌

          周圣斌            

个人信息           

职称   副研究员         

学历   博士

电话    0571-86080393        

邮箱   szz59@ucas.ac.cn

通讯地址 浙江省杭州市西湖区象山支弄1号1号楼3B-305

2010.9-2015.7  威斯尼斯人wns888入口中国上海药物研究所，药物化学，博士，导师：柳红研究员

2020.12至今威斯尼斯人wns888入口中国，药物科学与技术学院，副研究员

2016.6-2020.9美国宾夕法尼亚州立大学，化学系和生物化学及分子生物学系，博士后，

合作导师：J. Martin Bollinger, Jr.和Carsten Krebs

2015.7-2016.5威斯尼斯人wns888入口中国上海药物研究所，柳红组，助理研究员

1.天然产物药物及其衍生物的结构修饰及构效关系研究

2.天然产物生物合成路径中关键酶的作用机制研究，新功能表征及进化改造

3.活性天然产物潜在的作用机制研究

1. EV71 3C蛋白酶抑制剂的设计、合成及抗病毒活性研究，国自然青基（21602234），主持，

2.糖抑制剂合成技术服务，科研协作（2021HX01B05002），主持

3.糖类药物研发关键技术与品种，杭州市领军型创新创业团队项目（TD2020005），主持

2.Zhou, S.,^*Pan, J., Davis, K., Schaperdoth, I., Wang, B., Boal, A., Krebs, C.,^*Bollinger, J. M., Jr.^*Steric Enforcement ofcis-Epoxide Formation in the Radical C–O-Coupling Reaction by Which (S)-2-Hydroxypropylphosphonate Epoxidase (HppE) Produces Fosfomycin.J. Am. Chem. Soc.2019,141, 51, 20397-20406.JACS Spotlight.J. Am. Chem. Soc.2020,142, 6, 2697-2698.

3.Zhou, S.; Wang, S.; Wang, J.; Nian, Y.; Peng, P.; Soloshonok, V. A.; Liu, H., Configurationally Stable (S)- and (R)-α-Methylproline-Derived Ligands for the Direct Chemical Resolution of Free Unprotected β³-Amino Acids.Eur. J. Org. Chem.2018,15, 1821-1832.

4.Zhou, S.,^†Duan, Y.N.,^†Wang, J.,^†Zhang J., Sun, H., Jiang H, Gu Z, Tong J, Li J, Li, J., Liu, H. Design, synthesis and biological evaluation of 4,7,12,12a-tetrahydro-5H-thieno[3',2':3,4]pyrido[1,2-b]isoquinolines as novel adenosine 5'-monophosphate-activated protein kinase (AMPK) indirect activators for the treatment of type 2 diabetes.Eur. J. Med. Chem.2017,10, 448-464.

5.Zhou, S., Wang, J., Chen, X., Aceña, J., Soloshonok, V. A.,^*Liu, H.^*Chemical kinetic resolution of unprotected β-substituted-β-amino acids using recyclable chiral ligands.Angew. Chem. Int. Ed.2014,53, 7883-7886.

6.Zhou, S., Wang, J., Lin, D., Zhao, F., Liu, H. Enantioselective synthesis of 2-substitued-tetrahydroisoquinolin-1-yl glycine derivatives via oxidative cross-dehydrogenative coupling of tertiary amines and chiral nickel(II) glycinate.J. Org. Chem.2013,78, 11204-11212.

7.Zhou, S., Wang J., Liu, H. Lead compound optimization strategy (5) – reducing hERG cardiac toxicity in drug development. (Chinese Review).Acta Pharm. Sin., 2016,51, 1530-1539.

8.Li, T.,^†Zhou, S.,^†Wang, J., Acena, J. L., Soloshonok, V. A., Liu, H.Asymmetric Synthesis of (2S,3S)‑α-(1-Oxoisoindolin-3-yl)glycines under Low-Basicity “Kinetic” Control.J. Org. Chem.2015,80, 11275-11280.